Trial Master File Specialist

SK Life Science supports SUDEP awareness efforts through partnership with CURE Epilepsy and The Cameron Boyce Foundation. Oct 14, 2026, 11:48 ET SK Life Science to Match Donations Up to $10,000 to Advance SUDEP Research, Awareness, and Education Release Highlights: * SK Life Science to match donations to CURE Epilepsy up to $10,000 * Supporting SUDEP awareness efforts with CURE Epilepsy and The Cameron Boyce Foundation * Raising awareness of a serious but often under-discussed epilepsy-related risk * Reinforcing the need for education, informed conversations, and community empowerment * Advancing SK Life Science's commitment to the epilepsy community PARAMUS, N.J., Oct. 14, 2026 /PRNewswire/ - SK Life Science, Inc., a U.S. pharmaceutical company and part of SK Biopharmaceuticals, today announced its support of SUDEP awareness initiatives led by CURE Epilepsy and The Cameron Boyce Foundation during #StopSUDEP Week, October 19-23, and throughout the month of October. As part of its ongoing commitment to the epilepsy community, SK Life Science will match donations to CURE Epilepsy dollar for dollar up to $10,000, helping advance efforts to raise awareness of Sudden Unexpected Death in Epilepsy (SUDEP), support critical research, and provide educational resources for individuals and families impacted by epilepsy. SUDEP remains one of the most serious epilepsy-related risks. Through its longstanding support of CURE Epilepsy and The Cameron Boyce Foundation, SK Life Science is committed to helping ensure people living with epilepsy and their caregivers have access to information, resources, and conversations that empower them to make informed decisions alongside their healthcare teams. People living with epilepsy can work with their healthcare providers to support seizure management and discuss steps that may help reduce risk, including taking medications as prescribed, recognizing and avoiding personal seizure triggers, getting adequate sleep, limiting alcohol use, and considering nighttime monitoring when appropriate. "Knowledge empowers action, and meaningful conversations can help individuals and families feel more informed and confident in managing epilepsy," said Sunita Misra, Ph.D., M.D., Chief Medical Officer of SK Life Science. "Our research has shown that important conversations about SUDEP are not always reaching the people who need them most. That is why we are proud to support CURE Epilepsy and The Cameron Boyce Foundation in their efforts to raise awareness, encourage dialogue, and ensure the epilepsy community has access to educational resources that can help people better understand and address SUDEP risk." "SUDEP awareness saves lives through knowledge, conversation, and action," said Beth Lewin Dean, MBA, MPA, Chief Executive Officer of CURE Epilepsy. "We are grateful for SK Life Science's partnership and support of this campaign. Together with The Cameron Boyce Foundation and advocates across the epilepsy community, we are all working to ensure more individuals and families have access to information about SUDEP while accelerating the research needed to better understand and ultimately prevent these tragic losses." SK Life Science's support of SUDEP awareness efforts reflects the company's broader commitment to addressing educational gaps within the epilepsy community. Findings from the Hope, Hesitancy and Hard Truths survey revealed that nearly one in five people experiencing daily seizures reported they had either never heard of SUDEP or had not heard about it from their physician. The survey, available on www.sklifescienceinc.com, also found a disconnect between physician and patient discussions, with 88% of physicians reporting they discuss SUDEP compared with just 63% of patients recalling that conversation. These findings underscore the importance of continued education, awareness, and open dialogue about epilepsy-related risks. Throughout October, CURE Epilepsy and The Cameron Boyce Foundation are bringing attention to SUDEP through awareness, education, advocacy, and fundraising initiatives designed to increase understanding of epilepsy and support ongoing research. The campaign encourages individuals, families, healthcare professionals, and advocates to learn about SUDEP, share resources, honor loved ones, and support efforts aimed at reducing epilepsy-related deaths. At SK Life Science, supporting the epilepsy community extends beyond developing medicines. Through partnerships with organizations such as CURE Epilepsy and The Cameron Boyce Foundation, the company remains committed to advancing education, supporting research, and empowering individuals and families affected by epilepsy. For more information about SK Life Science's commitment to the epilepsy community, visit www.sklifescienceinc.com. About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd. SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with 12 compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content screening, computer-aided drug design, combinatorial chemistry, and integrating artificial intelligence across discovery, development, and operations to accelerate innovation, the companies drive R&D efforts in biology/discovery, medicinal chemistry, pharmacology, and clinical development. For more information, visit www.sklifescienceinc.com. SOURCE SK Life Science, Inc.

SK Biopharmaceuticals licenses Biohaven epilepsy drug opakalim. Healthcare Supply Chain August 30, 2026 Highlights. * SK Biopharmaceuticals is expanding its U.S. strategy with a deal for the late-stage epilepsy drug opakalim from Biohaven. * SK will pay $400 million up front for global rights to opakalim, with additional milestone payments and royalties possible. * The drug is in Phase 3 testing for focal onset epilepsy, and SK plans a U.S. launch in 2029 if it wins FDA approval. SK Biopharmaceuticals, a South Korea-based drugmaker that already sells an FDA-approved epilepsy medicine, is expanding its U.S. strategy through a deal for opakalim, a late-stage molecule from Biohaven. The drug uses a different mechanism of action for seizure disorder treatment. According to the terms announced Aug. 26, SK will pay $400 million up front for global rights to the Biohaven drug. The payment includes $350 million at deal closing and $50 million one year later. SK could pay Biohaven up to $395 million more tied to milestones, along with royalties from sales of an approved product. A portion of those payments will go to Knopp Biosciences, which originally developed opakalim and formed Channel Bio. Biohaven has advanced opakalim to Phase 3 testing in focal onset epilepsy. Preliminary Phase 2/3 data are expected by the end of this year, and a second readout is expected in 2028. If the drug passes FDA review, SK said it plans to launch opakalim in the U.S. in 2029 through SK Life Science, its New Jersey-based subsidiary. Biohaven added opakalim to its pipeline through the $100 million purchase of Channel Bio in 2022. Analysts said the deal gives Biohaven non-dilutive capital and allows it to focus on other pipeline programs, including taldefgrobep alfa, BHV-1300, and BHV-1400. The company reported cash of about $270.5 million as of June 30. company spotlight Osirium. In the current world of outsourcing, it can be hard to see who has privileged access to what on your systems. These days, the lowest paid people have the highest privileges - and they may not even work for your organisation. Osirium readdresses this balance for end-user organisations and uniquely allows MSSPs to manage tens of thousands of account credentials, outsource safely and keep their clients happy on the compliance front. more top stories August 31, 2026 * Health tech companies announced several major funding rounds in August. * Cityblock raised $116 million in Series E funding to support its acquisition of Homeward Health and invest in its combined platform. * Happy Health, Flagler Health, and Network Bio also reported funding rounds of $75 million, $50 million, and $50 million, respectively. Health tech companies made several major funding announcements in August, and the roundup highlighted some of the biggest funding rounds of the month. The list was presented as a selection of notable transactions and was not intended to be comprehensive. Cityblock raised $116 million in Series E funding. The New York City-based company offers clinical care, behavioral health care, and social care in patients' homes, virtually, and in community-based clinics. It primarily serves Medicaid and dual-eligible populations. The company's AI-powered operating system aggregates physical, behavioral, and social health data to provide care teams with predictive insights into members. The $116 million round supported Cityblock's acquisition of Homeward Health, a rural healthcare provider. The funding will be used to invest in the combined platform, including optimizing operations, the care model, technology, and data infrastructure. Happy Health secured $75 million in funding from ARCH Venture Partners and OpenLoop. Flagler Health raised $50 million in Series B funding led by Bessemer Venture Partners, and Network Bio launched with $50 million in funding from Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, and JSL Health Capital. August 31, 2026 * August brought a series of executive hires, exits, and layoffs across healthcare organizations. * New appointments included leaders at Adonis, Cone Health, Humana, Mayo Clinic, Merck, Providence, and Quantum Health. * Layoffs were announced by Cellares, MaineHealth, and Sharp HealthCare, while Centene and Tufts Medicine reported leadership exits. This monthly roundup highlights selected hiring news in healthcare and is not intended to be comprehensive. It includes executive appointments, resignations, promotions, and layoffs shared during the month. The roundup invites organizations to share news about an executive appointment, resignation, or layoff for future inclusion. Among the hires and promotions, Adonis named Alison Bloom-Kiefer as chief product officer and promoted Doug Pickett to chief revenue officer. Cone Health appointed Ryan Christensen as chief value-based care officer, while Humana selected J.P Holland as its new Medicaid president. Mayo Clinic named Arun Kumar Bhaskara-Baba as its new CIO, and Merck brought in Bart Gourley as chief AI officer. Providence named Kevin Smith as its new CFO, with a planned start in October after he leaves SSM Health. Quantum Health hired Jamie Hall as chief commercial officer and Daniel Stein as chief strategy officer. The roundup also noted that Bloom-Kiefer joined Adonis from Oscar Health, Pickett came from Cedar, Holland joined from Johns Hopkins Health Plans, and Bhaskara-Baba arrived from Honeywell Aerospace and Defense. On the exits side, Centene CFO Drew Asher said he will retire at the end of the year after serving since 2021. Tufts Medicine CEO Mike Dandorph and CFO Andrew Devoe also announced they are stepping down as the health system begins a major financial turnaround effort. In layoffs, Cellares said it plans to cut about 100 employees after Bristol Myers Squibb ended its manufacturing partnership, while MaineHealth is cutting 83 positions and Sharp HealthCare said 260 employees are affected by an organizational realignment.